Consainsights logo
Reports / Anti-tuberculosis Therapeutics Market

Anti-tuberculosis Therapeutics Market

Anti-tuberculosis Therapeutics Market Research Report – Segmented By Drug Class (Amynoglycosides, Bedaquiline, Cyclic Peptides, Ethambutol, Fluoroquinolones, Isoniazid, Other Drug Classes, Pyrazinamide, Rifampin, Thioamides), End User (Government Agencies, Hospitals and Clinics, Non Profit Organizations, Other End Users) & Region (North America, Europe, APAC, Latin America, Middle East and Africa) – Analysis on Size, Share, Trends, COVID-19 Impact, Competitive Analysis, Growth Opportunities and Key Insights from 2017 to 2026.


01

Executive Summary

Anti-tuberculosis Therapeutics Market was valued at US $1,344.85 million in 2021 and is projected to grow at 6.21% CAGR over the forecast period to reach US $1,930.02 million by 2027. Anti-tuberculosis Therapeutics Market represented US $152.57 million opportunity over 2019-2021 and estimated to create US $585.17 million opportunity in 2027 over 2021.

Anti-tuberculosis Therapeutics from Consainsights analyses the Anti-tuberculosis Therapeutics Market in the Life Sciences industry over the forecast period to 2027.

Anti-tuberculosis Therapeutics research report from Consainsights outlines the detailed strategic analysis, trends, market opportunities, growth prospects, industry and market challenges and sustainable solutions to sustain in the competitive environment.

Anti-tuberculosis Therapeutics segmentation includes Drug Class, End User and Geography.

Based on the Drug Class, the Anti-tuberculosis Therapeutics analysis covers Isoniazid, Rifampin, Ethambutol, Pyrazinamide, Fluoroquinolones, Bedaquiline, Amynoglycosides, Thioamides, Cyclic Peptides, Other Drug Classes.

In Drug Class segment, Isoniazid segment has highest cagr growth of 5.50%.

Based on the End User, the Anti-tuberculosis Therapeutics analysis covers Hospitals and Clinics, Government Agencies, Non Profit Organizations, Other End Users.

In End User segment, Government Agencies segment has highest cagr growth of 5.50%.

Based on the region, the Anti-tuberculosis Therapeutics analysis covers North America, Europe, Asia-Pacific, Middle-East & Africa, Latin America.

Key companies operating in the market include Lupin Limited, Macleods Pharmaceuticals Ltd, Otsuka Pharmaceutical Co. Ltd, Johnson and Johnson, Pfizer Inc., Novartis AG and so on. This report covers the detailed analysis of the company profiles such as business segments, product portfolio, key brand insights and growth strategies adopted, company SWOT and Strategy analysis along with the financial analysis and analyst insights on the key companies operating in this market.

  • Revenue Share (%), By Drug Class (2021)
    Revenue Share (%), By Drug Class (2021)
  • Revenue Share (%), By End User (2021)
    Revenue Share (%), By End User (2021)
02

Market Overview

  • The base currency considered was the US Dollar (USD). Conversion of other currencies to USD was considered on the basis of the average exchange rate for the respective review-period years. The exchange rate conversion for forecast period was determined according to the base year’s conversion rates.
  • The base year was identified based on the availability of annual reports and secondary information. The base year considered for this study is 2027.
  • The review period considered for this study is from 2018-2027. The CAGR is for the forecast period, 2022-2027.
  • Market size estimations for the forecast years were in real terms. Inflation is not part of the pricing, and the average selling price (ASP) was kept constant throughout the forecast period for each country.
  • Distribution of primary interviews conducted was based on the regional share of the market and the presence of key players in each region.
  • As a result of data triangulation through multiple methodologies and approaches, the weighted averages of resulting estimates were considered to be the final values.
  • The currency used in this report is USD, with the market size indicated in terms of USD million/billion.
  • For companies reporting their revenues in USD, the revenues were taken from their respective annual reports/SEC filings.
  • For companies reporting their revenues in other currencies, the average annual currency conversion rates were used for a particular year to convert the value to USD Market Definition.
03

By Drug Class

  • Isoniazid accounted for US$517.53 Bn in year 2021 and is expected to reach US$XX Bn in year 2027.
  • Rifampin accounted for US$321.98 Bn in year 2021 and is expected to reach US$XX Bn in year 2027.
  • Ethambutol accounted for US$203.00 Bn in year 2021 and is expected to reach US$XX Bn in year 2027.
  • Pyrazinamide accounted for US$125.65 Bn in year 2021 and is expected to reach US$XX Bn in year 2027.
  • Fluoroquinolones accounted for US$72.06 Bn in year 2021 and is expected to reach US$XX Bn in year 2027.
  • Bedaquiline accounted for US$42.19 Bn in year 2021 and is expected to reach US$XX Bn in year 2027.
  • Amynoglycosides accounted for US$24.72 Bn in year 2021 and is expected to reach US$XX Bn in year 2027.
  • Thioamides accounted for US$20.44 Bn in year 2021 and is expected to reach US$XX Bn in year 2027.
  • Cyclic Peptides accounted for US$8.85 Bn in year 2021 and is expected to reach US$XX Bn in year 2027.
  • Other Drug Classes accounted for US$8.43 Bn in year 2021 and is expected to reach US$XX Bn in year 2027.
Anti-tuberculosis Therapeutics Market Y-o-Y Growth (USD million), By Drug Class 2019 - 2027
Anti-tuberculosis Therapeutics Market Y-o-Y Growth (USD million), By Drug Class 2019 - 2027
Anti-tuberculosis Therapeutics Market Size, By Drug Class, 2019-2027 (USD million)
Anti-tuberculosis Therapeutics Market Size, By Drug Class, 2019-2027 (USD million)

The Amynoglycosides segment market was valued at US$ XX Mn in 2019 and grown at XX% CAGR over the historic years (2019 - 2027) to reach US$ XX Mn and is projected to grow at XX% CAGR over the forecast period to reach US$ XX Mn by 2027. The market represented the US$ XX Mn opportunity over 2019 - 2027 and estimated to create US$ XX Mn opportunity over 2019 - 2027.

Amynoglycosides: global Anti-tuberculosis Therapeutics Market Revenue Opportunity (Us$ Mn)
Amynoglycosides: global Anti-tuberculosis Therapeutics Market Revenue Opportunity (Us$ Mn)

The Bedaquiline segment market was valued at US$ XX Mn in 2019 and grown at XX% CAGR over the historic years (2019 - 2027) to reach US$ XX Mn and is projected to grow at XX% CAGR over the forecast period to reach US$ XX Mn by 2027. The market represented the US$ XX Mn opportunity over 2019 - 2027 and estimated to create US$ XX Mn opportunity over 2019 - 2027.

Bedaquiline: global Anti-tuberculosis Therapeutics Market Revenue Opportunity (Us$ Mn)
Bedaquiline: global Anti-tuberculosis Therapeutics Market Revenue Opportunity (Us$ Mn)

The Cyclic Peptides segment market was valued at US$ XX Mn in 2019 and grown at XX% CAGR over the historic years (2019 - 2027) to reach US$ XX Mn and is projected to grow at XX% CAGR over the forecast period to reach US$ XX Mn by 2027. The market represented the US$ XX Mn opportunity over 2019 - 2027 and estimated to create US$ XX Mn opportunity over 2019 - 2027.

Cyclic Peptides: global Anti-tuberculosis Therapeutics Market Revenue Opportunity (Us$ Mn)
Cyclic Peptides: global Anti-tuberculosis Therapeutics Market Revenue Opportunity (Us$ Mn)

The Ethambutol segment market was valued at US$ XX Mn in 2019 and grown at XX% CAGR over the historic years (2019 - 2027) to reach US$ XX Mn and is projected to grow at XX% CAGR over the forecast period to reach US$ XX Mn by 2027. The market represented the US$ XX Mn opportunity over 2019 - 2027 and estimated to create US$ XX Mn opportunity over 2019 - 2027.

Ethambutol: global Anti-tuberculosis Therapeutics Market Revenue Opportunity (Us$ Mn)
Ethambutol: global Anti-tuberculosis Therapeutics Market Revenue Opportunity (Us$ Mn)

The Fluoroquinolones segment market was valued at US$ XX Mn in 2019 and grown at XX% CAGR over the historic years (2019 - 2027) to reach US$ XX Mn and is projected to grow at XX% CAGR over the forecast period to reach US$ XX Mn by 2027. The market represented the US$ XX Mn opportunity over 2019 - 2027 and estimated to create US$ XX Mn opportunity over 2019 - 2027.

Fluoroquinolones: global Anti-tuberculosis Therapeutics Market Revenue Opportunity (Us$ Mn)
Fluoroquinolones: global Anti-tuberculosis Therapeutics Market Revenue Opportunity (Us$ Mn)

The Isoniazid segment market was valued at US$ XX Mn in 2019 and grown at XX% CAGR over the historic years (2019 - 2027) to reach US$ XX Mn and is projected to grow at XX% CAGR over the forecast period to reach US$ XX Mn by 2027. The market represented the US$ XX Mn opportunity over 2019 - 2027 and estimated to create US$ XX Mn opportunity over 2019 - 2027.

Isoniazid: global Anti-tuberculosis Therapeutics Market Revenue Opportunity (Us$ Mn)
Isoniazid: global Anti-tuberculosis Therapeutics Market Revenue Opportunity (Us$ Mn)

The Other Drug Classes segment market was valued at US$ XX Mn in 2019 and grown at XX% CAGR over the historic years (2019 - 2027) to reach US$ XX Mn and is projected to grow at XX% CAGR over the forecast period to reach US$ XX Mn by 2027. The market represented the US$ XX Mn opportunity over 2019 - 2027 and estimated to create US$ XX Mn opportunity over 2019 - 2027.

Other Drug Classes: global Anti-tuberculosis Therapeutics Market Revenue Opportunity (Us$ Mn)
Other Drug Classes: global Anti-tuberculosis Therapeutics Market Revenue Opportunity (Us$ Mn)

The Pyrazinamide segment market was valued at US$ XX Mn in 2019 and grown at XX% CAGR over the historic years (2019 - 2027) to reach US$ XX Mn and is projected to grow at XX% CAGR over the forecast period to reach US$ XX Mn by 2027. The market represented the US$ XX Mn opportunity over 2019 - 2027 and estimated to create US$ XX Mn opportunity over 2019 - 2027.

Pyrazinamide: global Anti-tuberculosis Therapeutics Market Revenue Opportunity (Us$ Mn)
Pyrazinamide: global Anti-tuberculosis Therapeutics Market Revenue Opportunity (Us$ Mn)

The Rifampin segment market was valued at US$ XX Mn in 2019 and grown at XX% CAGR over the historic years (2019 - 2027) to reach US$ XX Mn and is projected to grow at XX% CAGR over the forecast period to reach US$ XX Mn by 2027. The market represented the US$ XX Mn opportunity over 2019 - 2027 and estimated to create US$ XX Mn opportunity over 2019 - 2027.

Rifampin: global Anti-tuberculosis Therapeutics Market Revenue Opportunity (Us$ Mn)
Rifampin: global Anti-tuberculosis Therapeutics Market Revenue Opportunity (Us$ Mn)

The Thioamides segment market was valued at US$ XX Mn in 2019 and grown at XX% CAGR over the historic years (2019 - 2027) to reach US$ XX Mn and is projected to grow at XX% CAGR over the forecast period to reach US$ XX Mn by 2027. The market represented the US$ XX Mn opportunity over 2019 - 2027 and estimated to create US$ XX Mn opportunity over 2019 - 2027.

Thioamides: global Anti-tuberculosis Therapeutics Market Revenue Opportunity (Us$ Mn)
Thioamides: global Anti-tuberculosis Therapeutics Market Revenue Opportunity (Us$ Mn)
04

By End User

  • Hospitals and Clinics accounted for US$575.88 Bn in year 2021 and is expected to reach US$XX Bn in year 2027.
  • Government Agencies accounted for US$454.96 Bn in year 2021 and is expected to reach US$XX Bn in year 2027.
  • Non Profit Organizations accounted for US$130.95 Bn in year 2021 and is expected to reach US$XX Bn in year 2027.
  • Other End Users accounted for US$183.06 Bn in year 2021 and is expected to reach US$XX Bn in year 2027.
Anti-tuberculosis Therapeutics Market Y-o-Y Growth (USD million), By End User 2019 - 2027
Anti-tuberculosis Therapeutics Market Y-o-Y Growth (USD million), By End User 2019 - 2027
Anti-tuberculosis Therapeutics Market Size, By End User, 2019-2027 (USD million)
Anti-tuberculosis Therapeutics Market Size, By End User, 2019-2027 (USD million)

The Government Agencies segment market was valued at US$ XX Mn in 2019 and grown at XX% CAGR over the historic years (2019 - 2027) to reach US$ XX Mn and is projected to grow at XX% CAGR over the forecast period to reach US$ XX Mn by 2027. The market represented the US$ XX Mn opportunity over 2019 - 2027 and estimated to create US$ XX Mn opportunity over 2019 - 2027.

Government Agencies: global Anti-tuberculosis Therapeutics Market Revenue Opportunity (Us$ Mn)
Government Agencies: global Anti-tuberculosis Therapeutics Market Revenue Opportunity (Us$ Mn)

The Hospitals and Clinics segment market was valued at US$ XX Mn in 2019 and grown at XX% CAGR over the historic years (2019 - 2027) to reach US$ XX Mn and is projected to grow at XX% CAGR over the forecast period to reach US$ XX Mn by 2027. The market represented the US$ XX Mn opportunity over 2019 - 2027 and estimated to create US$ XX Mn opportunity over 2019 - 2027.

Hospitals and Clinics: global Anti-tuberculosis Therapeutics Market Revenue Opportunity (Us$ Mn)
Hospitals and Clinics: global Anti-tuberculosis Therapeutics Market Revenue Opportunity (Us$ Mn)

The Non Profit Organizations segment market was valued at US$ XX Mn in 2019 and grown at XX% CAGR over the historic years (2019 - 2027) to reach US$ XX Mn and is projected to grow at XX% CAGR over the forecast period to reach US$ XX Mn by 2027. The market represented the US$ XX Mn opportunity over 2019 - 2027 and estimated to create US$ XX Mn opportunity over 2019 - 2027.

Non Profit Organizations: global Anti-tuberculosis Therapeutics Market Revenue Opportunity (Us$ Mn)
Non Profit Organizations: global Anti-tuberculosis Therapeutics Market Revenue Opportunity (Us$ Mn)

The Other End Users segment market was valued at US$ XX Mn in 2019 and grown at XX% CAGR over the historic years (2019 - 2027) to reach US$ XX Mn and is projected to grow at XX% CAGR over the forecast period to reach US$ XX Mn by 2027. The market represented the US$ XX Mn opportunity over 2019 - 2027 and estimated to create US$ XX Mn opportunity over 2019 - 2027.

Other End Users: global Anti-tuberculosis Therapeutics Market Revenue Opportunity (Us$ Mn)
Other End Users: global Anti-tuberculosis Therapeutics Market Revenue Opportunity (Us$ Mn)
05

North America

  • In 2021, North America segment accounted for US$1344.85 Bn and is expected grow with a CAGR of 6.21% over the forecast years.
  • In North America, United States accounted for US$1137.28 Bn in year 2021 and is expected to reach US$XX Bn in year 2027.
  • Canada accounted for US$207.57 Bn in year 2021 and is expected to reach US$XX Bn in year 2027.
North America Anti-tuberculosis Therapeutics Market, By Country, 2019-2027 (USD million)
North America Anti-tuberculosis Therapeutics Market, By Country, 2019-2027 (USD million)
North America Anti-tuberculosis Therapeutics Market - Market Opportunity (USD million), 2019, 2021 & 2027
North America Anti-tuberculosis Therapeutics Market - Market Opportunity (USD million), 2019, 2021 & 2027
Revenue Share (%), By Drug Class - North America (2021)
Revenue Share (%), By Drug Class - North America (2021)
Revenue Share (%), By End User - North America (2021)
Revenue Share (%), By End User - North America (2021)
North America Anti-tuberculosis Therapeutics Market, By Country, 2019-2027 (USD million)
North America Anti-tuberculosis Therapeutics Market, By Country, 2019-2027 (USD million)
United States Anti-tuberculosis Therapeutics Market - Historical, Forecast Market Sizes (US$ MN), By Drug Class, 2019-2027
United States Anti-tuberculosis Therapeutics Market - Historical, Forecast Market Sizes (US$ MN), By Drug Class, 2019-2027
United States Anti-tuberculosis Therapeutics Market - Historical, Forecast Market Sizes (US$ MN), By End User, 2019-2027
United States Anti-tuberculosis Therapeutics Market - Historical, Forecast Market Sizes (US$ MN), By End User, 2019-2027
Canada Anti-tuberculosis Therapeutics Market - Historical, Forecast Market Sizes (US$ MN), By Drug Class, 2019-2027
Canada Anti-tuberculosis Therapeutics Market - Historical, Forecast Market Sizes (US$ MN), By Drug Class, 2019-2027
Canada Anti-tuberculosis Therapeutics Market - Historical, Forecast Market Sizes (US$ MN), By End User, 2019-2027
Canada Anti-tuberculosis Therapeutics Market - Historical, Forecast Market Sizes (US$ MN), By End User, 2019-2027
06

Europe

  • In 2021, Europe segment accounted for US$1344.85 Bn and is expected grow with a CAGR of 6.21% over the forecast years.
  • In Europe, Germany accounted for US$509.43 Bn in year 2021 and is expected to reach US$XX Bn in year 2027.
  • United Kingdom accounted for US$328.99 Bn in year 2021 and is expected to reach US$XX Bn in year 2027.
  • France accounted for US$220.66 Bn in year 2021 and is expected to reach US$XX Bn in year 2027.
  • Spain accounted for US$128.05 Bn in year 2021 and is expected to reach US$XX Bn in year 2027.
  • Russia accounted for US$54.18 Bn in year 2021 and is expected to reach US$XX Bn in year 2027.
  • Italy accounted for US$72.94 Bn in year 2021 and is expected to reach US$XX Bn in year 2027.
  • Rest of Europe accounted for US$30.60 Bn in year 2021 and is expected to reach US$XX Bn in year 2027.
Europe Anti-tuberculosis Therapeutics Market, By Country, 2019-2027 (USD million)
Europe Anti-tuberculosis Therapeutics Market, By Country, 2019-2027 (USD million)
Europe Anti-tuberculosis Therapeutics Market - Market Opportunity (USD million), 2019, 2021 & 2027
Europe Anti-tuberculosis Therapeutics Market - Market Opportunity (USD million), 2019, 2021 & 2027
Revenue Share (%), By Drug Class - Europe (2021)
Revenue Share (%), By Drug Class - Europe (2021)
Revenue Share (%), By End User - Europe (2021)
Revenue Share (%), By End User - Europe (2021)
Europe Anti-tuberculosis Therapeutics Market, By Country, 2019-2027 (USD million)
Europe Anti-tuberculosis Therapeutics Market, By Country, 2019-2027 (USD million)
Germany Anti-tuberculosis Therapeutics Market - Historical, Forecast Market Sizes (US$ MN), By Drug Class, 2019-2027
Germany Anti-tuberculosis Therapeutics Market - Historical, Forecast Market Sizes (US$ MN), By Drug Class, 2019-2027
Germany Anti-tuberculosis Therapeutics Market - Historical, Forecast Market Sizes (US$ MN), By End User, 2019-2027
Germany Anti-tuberculosis Therapeutics Market - Historical, Forecast Market Sizes (US$ MN), By End User, 2019-2027
United Kingdom Anti-tuberculosis Therapeutics Market - Historical, Forecast Market Sizes (US$ MN), By Drug Class, 2019-2027
United Kingdom Anti-tuberculosis Therapeutics Market - Historical, Forecast Market Sizes (US$ MN), By Drug Class, 2019-2027
United Kingdom Anti-tuberculosis Therapeutics Market - Historical, Forecast Market Sizes (US$ MN), By End User, 2019-2027
United Kingdom Anti-tuberculosis Therapeutics Market - Historical, Forecast Market Sizes (US$ MN), By End User, 2019-2027
France Anti-tuberculosis Therapeutics Market - Historical, Forecast Market Sizes (US$ MN), By Drug Class, 2019-2027
France Anti-tuberculosis Therapeutics Market - Historical, Forecast Market Sizes (US$ MN), By Drug Class, 2019-2027
France Anti-tuberculosis Therapeutics Market - Historical, Forecast Market Sizes (US$ MN), By End User, 2019-2027
France Anti-tuberculosis Therapeutics Market - Historical, Forecast Market Sizes (US$ MN), By End User, 2019-2027
Spain Anti-tuberculosis Therapeutics Market - Historical, Forecast Market Sizes (US$ MN), By Drug Class, 2019-2027
Spain Anti-tuberculosis Therapeutics Market - Historical, Forecast Market Sizes (US$ MN), By Drug Class, 2019-2027
Spain Anti-tuberculosis Therapeutics Market - Historical, Forecast Market Sizes (US$ MN), By End User, 2019-2027
Spain Anti-tuberculosis Therapeutics Market - Historical, Forecast Market Sizes (US$ MN), By End User, 2019-2027
Russia Anti-tuberculosis Therapeutics Market - Historical, Forecast Market Sizes (US$ MN), By Drug Class, 2019-2027
Russia Anti-tuberculosis Therapeutics Market - Historical, Forecast Market Sizes (US$ MN), By Drug Class, 2019-2027
Russia Anti-tuberculosis Therapeutics Market - Historical, Forecast Market Sizes (US$ MN), By End User, 2019-2027
Russia Anti-tuberculosis Therapeutics Market - Historical, Forecast Market Sizes (US$ MN), By End User, 2019-2027
Italy Anti-tuberculosis Therapeutics Market - Historical, Forecast Market Sizes (US$ MN), By Drug Class, 2019-2027
Italy Anti-tuberculosis Therapeutics Market - Historical, Forecast Market Sizes (US$ MN), By Drug Class, 2019-2027
Italy Anti-tuberculosis Therapeutics Market - Historical, Forecast Market Sizes (US$ MN), By End User, 2019-2027
Italy Anti-tuberculosis Therapeutics Market - Historical, Forecast Market Sizes (US$ MN), By End User, 2019-2027
Rest of Europe Anti-tuberculosis Therapeutics Market - Historical, Forecast Market Sizes (US$ MN), By Drug Class, 2019-2027
Rest of Europe Anti-tuberculosis Therapeutics Market - Historical, Forecast Market Sizes (US$ MN), By Drug Class, 2019-2027
Rest of Europe Anti-tuberculosis Therapeutics Market - Historical, Forecast Market Sizes (US$ MN), By End User, 2019-2027
Rest of Europe Anti-tuberculosis Therapeutics Market - Historical, Forecast Market Sizes (US$ MN), By End User, 2019-2027
07

Asia-Pacific

  • In 2021, Asia-Pacific segment accounted for US$1344.85 Bn and is expected grow with a CAGR of 6.21% over the forecast years.
  • In Asia-Pacific, China accounted for US$540.85 Bn in year 2021 and is expected to reach US$XX Bn in year 2027.
  • Japan accounted for US$341.42 Bn in year 2021 and is expected to reach US$XX Bn in year 2027.
  • India accounted for US$202.16 Bn in year 2021 and is expected to reach US$XX Bn in year 2027.
  • Southeast Asia accounted for US$140.39 Bn in year 2021 and is expected to reach US$XX Bn in year 2027.
  • Australia & New Zealand accounted for US$88.00 Bn in year 2021 and is expected to reach US$XX Bn in year 2027.
  • Rest of Asia-Pacific accounted for US$32.04 Bn in year 2021 and is expected to reach US$XX Bn in year 2027.
Asia-Pacific Anti-tuberculosis Therapeutics Market, By Country, 2019-2027 (USD million)
Asia-Pacific Anti-tuberculosis Therapeutics Market, By Country, 2019-2027 (USD million)
Asia-Pacific Anti-tuberculosis Therapeutics Market - Market Opportunity (USD million), 2019, 2021 & 2027
Asia-Pacific Anti-tuberculosis Therapeutics Market - Market Opportunity (USD million), 2019, 2021 & 2027
Revenue Share (%), By Drug Class - Asia-Pacific (2021)
Revenue Share (%), By Drug Class - Asia-Pacific (2021)
Revenue Share (%), By End User - Asia-Pacific (2021)
Revenue Share (%), By End User - Asia-Pacific (2021)
Asia-Pacific Anti-tuberculosis Therapeutics Market, By Country, 2019-2027 (USD million)
Asia-Pacific Anti-tuberculosis Therapeutics Market, By Country, 2019-2027 (USD million)
China Anti-tuberculosis Therapeutics Market - Historical, Forecast Market Sizes (US$ MN), By Drug Class, 2019-2027
China Anti-tuberculosis Therapeutics Market - Historical, Forecast Market Sizes (US$ MN), By Drug Class, 2019-2027
China Anti-tuberculosis Therapeutics Market - Historical, Forecast Market Sizes (US$ MN), By End User, 2019-2027
China Anti-tuberculosis Therapeutics Market - Historical, Forecast Market Sizes (US$ MN), By End User, 2019-2027
Japan Anti-tuberculosis Therapeutics Market - Historical, Forecast Market Sizes (US$ MN), By Drug Class, 2019-2027
Japan Anti-tuberculosis Therapeutics Market - Historical, Forecast Market Sizes (US$ MN), By Drug Class, 2019-2027
Japan Anti-tuberculosis Therapeutics Market - Historical, Forecast Market Sizes (US$ MN), By End User, 2019-2027
Japan Anti-tuberculosis Therapeutics Market - Historical, Forecast Market Sizes (US$ MN), By End User, 2019-2027
India Anti-tuberculosis Therapeutics Market - Historical, Forecast Market Sizes (US$ MN), By Drug Class, 2019-2027
India Anti-tuberculosis Therapeutics Market - Historical, Forecast Market Sizes (US$ MN), By Drug Class, 2019-2027
India Anti-tuberculosis Therapeutics Market - Historical, Forecast Market Sizes (US$ MN), By End User, 2019-2027
India Anti-tuberculosis Therapeutics Market - Historical, Forecast Market Sizes (US$ MN), By End User, 2019-2027
Southeast Asia Anti-tuberculosis Therapeutics Market - Historical, Forecast Market Sizes (US$ MN), By Drug Class, 2019-2027
Southeast Asia Anti-tuberculosis Therapeutics Market - Historical, Forecast Market Sizes (US$ MN), By Drug Class, 2019-2027
Southeast Asia Anti-tuberculosis Therapeutics Market - Historical, Forecast Market Sizes (US$ MN), By End User, 2019-2027
Southeast Asia Anti-tuberculosis Therapeutics Market - Historical, Forecast Market Sizes (US$ MN), By End User, 2019-2027
Australia & New Zealand Anti-tuberculosis Therapeutics Market - Historical, Forecast Market Sizes (US$ MN), By Drug Class, 2019-2027
Australia & New Zealand Anti-tuberculosis Therapeutics Market - Historical, Forecast Market Sizes (US$ MN), By Drug Class, 2019-2027
Australia & New Zealand Anti-tuberculosis Therapeutics Market - Historical, Forecast Market Sizes (US$ MN), By End User, 2019-2027
Australia & New Zealand Anti-tuberculosis Therapeutics Market - Historical, Forecast Market Sizes (US$ MN), By End User, 2019-2027
Rest of Asia-Pacific Anti-tuberculosis Therapeutics Market - Historical, Forecast Market Sizes (US$ MN), By Drug Class, 2019-2027
Rest of Asia-Pacific Anti-tuberculosis Therapeutics Market - Historical, Forecast Market Sizes (US$ MN), By Drug Class, 2019-2027
Rest of Asia-Pacific Anti-tuberculosis Therapeutics Market - Historical, Forecast Market Sizes (US$ MN), By End User, 2019-2027
Rest of Asia-Pacific Anti-tuberculosis Therapeutics Market - Historical, Forecast Market Sizes (US$ MN), By End User, 2019-2027
08

Middle East & Africa

Based on the Middle East & Africa, the Anti-tuberculosis Therapeutics Market analysis covers Middle East, Africa, Rest of Middle East & Africa.

Middle East & Africa Map
Middle East & Africa Anti-tuberculosis Therapeutics Market Size, 2019-2027 (Us$ Mn)
Middle East & Africa Anti-tuberculosis Therapeutics Size, 2019-2027 (Us$ Mn)
Middle East & Africa Anti-tuberculosis Therapeutics Market - Historical, Forecast Market Sizes (US$ MN), By Drug Class, 2019-2027
Middle East & Africa Anti-tuberculosis Therapeutics Market - Historical, Forecast Market Sizes (US$ MN), By Drug Class, 2019-2027
Middle East & Africa Anti-tuberculosis Therapeutics Market - Historical, Forecast Market Sizes (US$ MN), By End User, 2019-2027
Middle East & Africa Anti-tuberculosis Therapeutics Market - Historical, Forecast Market Sizes (US$ MN), By End User, 2019-2027
Middle East Anti-tuberculosis Therapeutics Market - Historical, Forecast Market Sizes (US$ MN), By Drug Class, 2019-2027
Middle East Anti-tuberculosis Therapeutics Market - Historical, Forecast Market Sizes (US$ MN), By Drug Class, 2019-2027
Middle East Anti-tuberculosis Therapeutics Market - Historical, Forecast Market Sizes (US$ MN), By End User, 2019-2027
Middle East Anti-tuberculosis Therapeutics Market - Historical, Forecast Market Sizes (US$ MN), By End User, 2019-2027
Africa Anti-tuberculosis Therapeutics Market - Historical, Forecast Market Sizes (US$ MN), By Drug Class, 2019-2027
Africa Anti-tuberculosis Therapeutics Market - Historical, Forecast Market Sizes (US$ MN), By Drug Class, 2019-2027
Africa Anti-tuberculosis Therapeutics Market - Historical, Forecast Market Sizes (US$ MN), By End User, 2019-2027
Africa Anti-tuberculosis Therapeutics Market - Historical, Forecast Market Sizes (US$ MN), By End User, 2019-2027
Rest of Middle East & Africa Anti-tuberculosis Therapeutics Market - Historical, Forecast Market Sizes (US$ MN), By Drug Class, 2019-2027
Rest of Middle East & Africa Anti-tuberculosis Therapeutics Market - Historical, Forecast Market Sizes (US$ MN), By Drug Class, 2019-2027
Rest of Middle East & Africa Anti-tuberculosis Therapeutics Market - Historical, Forecast Market Sizes (US$ MN), By End User, 2019-2027
Rest of Middle East & Africa Anti-tuberculosis Therapeutics Market - Historical, Forecast Market Sizes (US$ MN), By End User, 2019-2027
09

Latin America

  • In 2021, Latin America segment accounted for US$1344.85 Bn and is expected grow with a CAGR of 6.21% over the forecast years.
  • In Latin America, Brazil accounted for US$619.66 Bn in year 2021 and is expected to reach US$XX Bn in year 2027.
  • Argentina accounted for US$385.56 Bn in year 2021 and is expected to reach US$XX Bn in year 2027.
  • Mexico accounted for US$155.88 Bn in year 2021 and is expected to reach US$XX Bn in year 2027.
  • Colombia accounted for US$146.78 Bn in year 2021 and is expected to reach US$XX Bn in year 2027.
  • Rest of Latin America accounted for US$36.97 Bn in year 2021 and is expected to reach US$XX Bn in year 2027.
Latin America Anti-tuberculosis Therapeutics Market, By Country, 2019-2027 (USD million)
Latin America Anti-tuberculosis Therapeutics Market, By Country, 2019-2027 (USD million)
Latin America Anti-tuberculosis Therapeutics Market - Market Opportunity (USD million), 2019, 2021 & 2027
Latin America Anti-tuberculosis Therapeutics Market - Market Opportunity (USD million), 2019, 2021 & 2027
Revenue Share (%), By Drug Class - Latin America (2021)
Revenue Share (%), By Drug Class - Latin America (2021)
Revenue Share (%), By End User - Latin America (2021)
Revenue Share (%), By End User - Latin America (2021)
Latin America Anti-tuberculosis Therapeutics Market, By Country, 2019-2027 (USD million)
Latin America Anti-tuberculosis Therapeutics Market, By Country, 2019-2027 (USD million)
Brazil Anti-tuberculosis Therapeutics Market - Historical, Forecast Market Sizes (US$ MN), By Drug Class, 2019-2027
Brazil Anti-tuberculosis Therapeutics Market - Historical, Forecast Market Sizes (US$ MN), By Drug Class, 2019-2027
Brazil Anti-tuberculosis Therapeutics Market - Historical, Forecast Market Sizes (US$ MN), By End User, 2019-2027
Brazil Anti-tuberculosis Therapeutics Market - Historical, Forecast Market Sizes (US$ MN), By End User, 2019-2027
Argentina Anti-tuberculosis Therapeutics Market - Historical, Forecast Market Sizes (US$ MN), By Drug Class, 2019-2027
Argentina Anti-tuberculosis Therapeutics Market - Historical, Forecast Market Sizes (US$ MN), By Drug Class, 2019-2027
Argentina Anti-tuberculosis Therapeutics Market - Historical, Forecast Market Sizes (US$ MN), By End User, 2019-2027
Argentina Anti-tuberculosis Therapeutics Market - Historical, Forecast Market Sizes (US$ MN), By End User, 2019-2027
Mexico Anti-tuberculosis Therapeutics Market - Historical, Forecast Market Sizes (US$ MN), By Drug Class, 2019-2027
Mexico Anti-tuberculosis Therapeutics Market - Historical, Forecast Market Sizes (US$ MN), By Drug Class, 2019-2027
Mexico Anti-tuberculosis Therapeutics Market - Historical, Forecast Market Sizes (US$ MN), By End User, 2019-2027
Mexico Anti-tuberculosis Therapeutics Market - Historical, Forecast Market Sizes (US$ MN), By End User, 2019-2027
Colombia Anti-tuberculosis Therapeutics Market - Historical, Forecast Market Sizes (US$ MN), By Drug Class, 2019-2027
Colombia Anti-tuberculosis Therapeutics Market - Historical, Forecast Market Sizes (US$ MN), By Drug Class, 2019-2027
Colombia Anti-tuberculosis Therapeutics Market - Historical, Forecast Market Sizes (US$ MN), By End User, 2019-2027
Colombia Anti-tuberculosis Therapeutics Market - Historical, Forecast Market Sizes (US$ MN), By End User, 2019-2027
Rest of Latin America Anti-tuberculosis Therapeutics Market - Historical, Forecast Market Sizes (US$ MN), By Drug Class, 2019-2027
Rest of Latin America Anti-tuberculosis Therapeutics Market - Historical, Forecast Market Sizes (US$ MN), By Drug Class, 2019-2027
Rest of Latin America Anti-tuberculosis Therapeutics Market - Historical, Forecast Market Sizes (US$ MN), By End User, 2019-2027
Rest of Latin America Anti-tuberculosis Therapeutics Market - Historical, Forecast Market Sizes (US$ MN), By End User, 2019-2027
10

Company Analysis

  • Lupin Limited
  • Macleods Pharmaceuticals Ltd
  • Otsuka Pharmaceutical Co. Ltd
  • Johnson and Johnson
  • Pfizer Inc.
  • Novartis AG